Corpus Intelligence IC Memo — KINDRED HOSPITAL SOUTH BAY 2026-04-26 14:21 UTC
IC Memo — KINDRED HOSPITAL SOUTH BAY
Investment Committee Memorandum | CA | 59 beds | Grade D | EBITDA uplift $2.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KINDRED HOSPITAL SOUTH BAY

CCN 052050 | LOS ANGELES, CA | 59 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

KINDRED HOSPITAL SOUTH BAY is a 59-bed suburban community hospital in LOS ANGELES, CA with $39.5M in net patient revenue and a -1.6% operating margin. The hospital serves a payer mix of 54.9% Medicare, 2.7% Medicaid, and 42.4% commercial.

Thesis: Turnaround. Our ML models identify $2.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -1.6% to 5.8% (+736bps).

Net Revenue HCRIS$39.5M
Current EBITDA COMPUTED$-628K
Operating Margin COMPUTED-1.6%
Occupancy HCRIS76.9%
Revenue / Bed COMPUTED$670K
Net-to-Gross HCRIS17.7%
Distress Probability ML42.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
119
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -1.6% places it above the state median. Among 119 size-comparable peers (30-118 beds), the median margin is -6.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (30-118), prioritizing same-state peers. 119 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KINDRED HOSPITAL SOUTH BAY (Target)CA59$39.5M-1.6%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - FREMONTCA100$296.2M-6.6%
MERCY HOSPITAL OF FOLSOMCA106$287.8M17.0%
MARSHALL HOSPITALCA111$286.0M-5.9%
LLUMC MURRIETACA111$276.7M-20.3%
ADVENTIST HEALTH SONORACA84$274.3M-7.4%
CPMC-R.K. DAVIES MEDICAL CENTECA105$243.7M24.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$830K+210bp18mo
Cost to Collect4.5%2.5%$790K+200bp12mo
Denial Rate Reduction12.0%6.5%$782K+198bp12mo
A/R Days Reduction5200.0%3800.0%$481K+122bp9mo
Clean Claim Rate88.0%96.0%$25K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$830K
Cost to Collect
$790K
Denial Rate Reduction
$782K
A/R Days Reduction
$481K
Clean Claim Rate
$25K
Total EBITDA Uplift$2.9M
Current EBITDA$-628K
+ RCM Uplift+$2.9M
Pro Forma EBITDA$2.3M
Current Margin-1.6%
Pro Forma Margin5.8%
WC Released (1x)$1.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-965K$24.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-965K$27.1M0.00x-100.0%
Bull Case9.0x11.0x$-869K$36.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-869K$39.5M0.00x-100.0%
Bear Case11.0x10.0x$-1.1M$10.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.1M$11.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 119 hospitals with 30-118 beds
  • Same-state prioritization (n=120)
  • Comp margins: P25=-23.3% / P50=-6.4% / P75=1.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.